EUDA News & Events

EUDA Health Holdings entered into a convertible loan agreement with Shenzhen Inno Immune. Under the terms of the agreement, EUDA expects to invest up to RMB 6M in two tranches, consisting of an initial tranche of RMB 1M and a second tranche of RMB 5M, subject to the completion of due diligence, regulatory approvals, and execution of definitive agreements. Shenzhen Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA's China strategy, anchoring EUDA's regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion into additional cities and markets. The investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation. The convertible loan note is expected to carry an interest rate of 6% per annum, payable semi-annually, and may be redeemed with accrued interest if not converted, subject to the final terms.

EUDA Health announced that it has entered into an amendment to its previously disclosed warrant agreement with Streeterville Capital. On December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant from $6.00 per share to $4.00 per share and (ii) reduce the minimum closing price required to trigger a "Forced Exercise" from $7.50 to $6.00. All other terms of the warrant remain unchanged.

EUDA Health Holdings announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. The company said, "This platform marks a major step in EUDA's continued advancement of its stem cell strategy, further extending its capabilities across cell extraction, processing, cryogenic storage, logistics and clinical application. EUDA's platform is designed around three core principles: centralized processing with decentralized access to ensure quality and compliance without limiting geographic reach, long-term cell preservation to enable patients to store biological material earlier in life for potential future clinical use, and integration with longevity medicine so that cell services are embedded within broader preventive, regenerative and personalized health programs. EUDA's platform is designed as a closed-loop, compliant operating system that enables patients to access stem cell services across a wide geographic footprint while maintaining centralized processing standards. Key elements include: Shenzhen Inno Immune as EUDA's primary cell processing and cryogenic storage hub in Southern China, with an initial designed cryogenic storage capacity of approximately 50,000 patient cell units under controlled conditions. Wuhan Kaien Hospital as EUDA's Central China clinical and longevity flagship, with a planned cryogenic biostorage and clinical capacity designed to support up to approximately 200,000 patient cell units, integrated with inpatient, outpatient and long-term health management services. A nationwide clinical access layer via partner clinic networks enabling local extraction and downstream clinical delivery."